ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
US |
|
Santana Minerals Ltd
ASX:SMI
|
AU |
|
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
ID |
Relative Value
The Relative Value of one
ACAD
stock under the Base Case scenario is
21.2
USD.
Compared to the current market price of 20.74 USD,
ACADIA Pharmaceuticals Inc
is
Undervalued by 2%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
ACAD Competitors Multiples
ACADIA Pharmaceuticals Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
3.5B USD | 3.3 | 9 | 17.8 | 19.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.5B USD | 5.9 | 86.6 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.3B USD | 5.8 | 20 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29.2 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.5B USD | 5.4 | 17.2 | 12.6 | 14.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.8B AUD | 3.1 | 34.3 | 11.3 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.3B USD | 11.1 | 131.9 | 73.8 | 82 |